0
ARTICLE |

Antihemophilic Factor Concentrate Therapy in von Willebrand Disease: Title and subTitle BreakDissociation of Bleeding-Time Factor and Ristocetin-Cofactor Activities FREE

Philip M. Blatt, MD; Kenneth M. Brinkhous, MD; Harry R. Culp; Jonathon S. Krauss, MD; Harold R. Roberts, MD
[+] Author Affiliations

Reprint requests to Department of Pathology, Room 707, University of North Carolina at Chapel Hill, Preclinical Educational Bldg 228-H, Chapel Hill, NC 27514 (Dr Roberts).


JAMA. 1976;236(24):2770-2772. doi:10.1001/jama.1976.03270250038023
Text Size: A A A
Published online

Treatment of von Willebrand disease with two plasma antihemophilic factor (AHF) concentrates, cryoprecipitate and glycine-precipitated AHF, was compared. Both concentrates were equally effective in immediately raising the plasma levels of factor VIII, the factor VIII-related antigen, and the ristocetin-related von Willebrand factor (vWF) and in stimulating a secondary rise in plasma factor VIII. Given either concentrate, the vWF activity, the antigen, and factor VIII levels were normalized in a patient with von Willebrand disease. However, correction of the prolonged bleeding time and control of bleeding occurred only with the cryoprecipitate. The bleeding-time corrective factor and the ristocetin-related vWF or platelet-aggregating factor are dissociable, distinct activities.

(JAMA 236:2770-2772, 1976)

REFERENCES

Bennett E, Dormandy K:  Pool's cryoprecipitate and exhausted plasma on the treatment of von Willebrand's disease and factor-XI deficiency . Lancet 2:731-732, 1966;.
Weiss HJ:  Relation of von Willebrand factor to bleeding time . N Engl J Med 291:420, 1974;.
Brinkhous KM, Shanbrom E, Roberts HR, et al:  A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate: Treatment of classical hemophilia and hemophilia with inhibitors . JAMA 205:613-617, 1968;.
Brinkhous KM, Graham JE, Cooper HA, et al:  Assay of von Willebrand factor in von Willebrand's disease and hemophilia: Use of a macroscopic platelet aggregation test . Thromb Res 6:267-272, 1975;.
Langdell RD, Wagner RH, Brinkhous KM:  Effect of antihemophilic factor on one-stage clotting tests . J Lab Clin Med 41:637-647, 1953;.
Zimmerman TS, Hoyer LW, Dickson L, et al:  Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis . J Lab Clin Med 86:152-159, 1975;.
Stratton RD, Wagner RH, Webster WP, et al:  Antibody nature of circulating inhibitor of plasma von Willebrand factor . Proc Natl Acad Sci USA 72:4167-4171, 1975;.
Perkins HA:  Correction of the hemostatic defects in von Willebrand's disease . Blood 30:375-380, 1967;.
Green D, Potter EV:  Failure of AHF concentrate to control bleeding in von Willebrand's disease . Am J Med 60:357-360, 1976;.
Griggs TR, Webster WP, Cooper HA, et al:  Von Willebrand factor: Gene dosage relationships and transfusion response in bleeder swine—a new bioassay . Proc Natl Acad Sci USA 71:2087-2090, 1974;.
Webster WP, Mandel SR, Strike LE, et al:  Factor VIII synthesis: Hepatic and renal allografts in swine with von Willebrand's disease . Am J Physiol 230:1342-1348, 1976;.
Muntz RH, Ekert H, Helliger H:  Properties of post-infusion factor VIII in von Willebrand's disease . Thromb Res 5:111-123, 1974;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Bennett E, Dormandy K:  Pool's cryoprecipitate and exhausted plasma on the treatment of von Willebrand's disease and factor-XI deficiency . Lancet 2:731-732, 1966;.
Weiss HJ:  Relation of von Willebrand factor to bleeding time . N Engl J Med 291:420, 1974;.
Brinkhous KM, Shanbrom E, Roberts HR, et al:  A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate: Treatment of classical hemophilia and hemophilia with inhibitors . JAMA 205:613-617, 1968;.
Brinkhous KM, Graham JE, Cooper HA, et al:  Assay of von Willebrand factor in von Willebrand's disease and hemophilia: Use of a macroscopic platelet aggregation test . Thromb Res 6:267-272, 1975;.
Langdell RD, Wagner RH, Brinkhous KM:  Effect of antihemophilic factor on one-stage clotting tests . J Lab Clin Med 41:637-647, 1953;.
Zimmerman TS, Hoyer LW, Dickson L, et al:  Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis . J Lab Clin Med 86:152-159, 1975;.
Stratton RD, Wagner RH, Webster WP, et al:  Antibody nature of circulating inhibitor of plasma von Willebrand factor . Proc Natl Acad Sci USA 72:4167-4171, 1975;.
Perkins HA:  Correction of the hemostatic defects in von Willebrand's disease . Blood 30:375-380, 1967;.
Green D, Potter EV:  Failure of AHF concentrate to control bleeding in von Willebrand's disease . Am J Med 60:357-360, 1976;.
Griggs TR, Webster WP, Cooper HA, et al:  Von Willebrand factor: Gene dosage relationships and transfusion response in bleeder swine—a new bioassay . Proc Natl Acad Sci USA 71:2087-2090, 1974;.
Webster WP, Mandel SR, Strike LE, et al:  Factor VIII synthesis: Hepatic and renal allografts in swine with von Willebrand's disease . Am J Physiol 230:1342-1348, 1976;.
Muntz RH, Ekert H, Helliger H:  Properties of post-infusion factor VIII in von Willebrand's disease . Thromb Res 5:111-123, 1974;.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.